Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Published:2006-12-15 Issue:13 Volume:108 Page:4003-4008
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:Blood

Author:

Forstpointner R.,Unterhalt M.,Dreyling M.,Bock H.-P.,Repp R.,Wandt H.,Pott C.,Seymour J. F.,Metzner B.,Hanel A.,Lehmann T.,Hartmann F.,Einsele H.,Hiddemann W.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Elderly Patients with Mantle Cell Lymphoma;2024-03-27

2. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

3. Treatment of relapsed follicular lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells;Cancer Medicine;2023-04-20

5. Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide;Journal of Clinical Oncology;2023-01-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP